February 25, 2013 / 9:25 PM / 5 years ago

Vivus reports bigger-than-expected 4th-qtr loss

Feb 25 (Reuters) - Vivus Inc’s revenue for the first full quarter of selling its diet pill Qsymia fell short of analysts’ estimates, and it posted a bigger-than-expected loss related to higher marketing expenses.

The company’s fourth-quarter net loss rose to $56.7 million, or 56 cents per share, from $11.5 million, or 13 cents per share, a year earlier.

Net product revenue, reflecting sales of Qsymia, was $2 million in the fourth quarter, compared with $41,000 reported in the third quarter.

Vivus started generating revenue from the third quarter, when it began selling Qsymia.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below